Malignant hyperthermia (MH) is an acute pharmacogenetic disorder, which develops during or immediately after the application of general anaesthesia. The classic MH crisis consists of a hyper-metabolic state caused primarily by continued contraction of the skeletal muscles, which leads to massive CO 2 production, skeletal muscle rigidity, tachyarrhythmias, unstable haemodynamics, respiratory acidosis, cyanosis, hyperkalaemia, lactic acidosis, fever and eventually (if untreated) death 1 .
The disorder is essentially a result of a defect in calcium homeostasis 2 , which can result from an alteration in DNA coding for the ryanodine receptor (RYR1) on chromosome 19q 3, 4 . Volatile anaesthetic agents and depolarising muscle relaxants interact with the calcium channel resulting in the clinical crisis.
The RYR1 gene is very large (contains a total of 106 exons and 15,000 bases of coding sequence). Mutations in three 'hot-spot' areas of the RYR1 gene have been shown to be functionally responsible for up to 50% of malignant hyperthermia susceptible (MHS) patients in European populations 5 . These areas include the N-terminal region between codons 34 and 614 (exons 2 to 19) , the central region between codons 2163 and 2458 (exons 39 to 47) and the C-terminal region between codons 4136 and 4973 (exons 85 to 104). The European Malignant Hyperthermia Group (EMHG) Guidelines 6 state that patients displaying one of the causative mutations in the RYR1 gene can be diagnosed as MHS without the need for a muscle biopsy.
The aim of this study was to identify mutations associated with MH in Australian families by direct sequencing of these previously outlined 'hot-spots' SUMMARY Advances in analysis of the RYR1 gene (which encodes the skeletal muscle ryanodine receptor) show that genetic examination is a useful adjunct to the in vitro contracture test in the diagnosis of malignant hyperthermia, as defects in RYR1 have been shown to be responsible for malignant hyperthermia susceptibility. DNA from 34 malignant hyperthermia susceptible individuals and four malignant hyperthermia equivocal subjects was examined using direct sequencing of 'hot-spots' in the RYR1 gene to identify mutations associated with malignant hyperthermia. Seven different causative mutations (as defined by the European Malignant Hyperthermia Group) in nine malignant hyperthermia susceptible individuals were identified. In another six malignant hyperthermia susceptible individuals, five different published but as yet functionally uncharacterised mutations were identified. A further three as yet unpublished and functionally uncharacterised (novel) mutations were identified in three malignant hyperthermia susceptible samples. If the novel and previously published mutations prove to be functionally associated with calcium homeostasis, then this method of analysis achieved a mutation detection rate of 47%. Based on the number of relatives presenting to our unit in the study period, the muscle biopsy rate would have decreased by 25%. That we only identified a genetic defect in RYR1 in 47% of in vitro contracture test positive individuals suggests that there are other areas in RYR1 where pathogenic mutations may occur and that RYR1 may not be the sole gene associated with malignant hyperthermia. It may also reflect a less than 100% specificity of the in vitro contracture test.
in the RYR1 gene and to use this information to decrease the number of family members requiring muscle biopsy and in vitro contracture test (IVCT) for diagnosis of MH. Secondary aims were to add to the international pool of RYR1 defects that may be associated with MH and to identify those mutations occurring more commonly in the Australian population.
MATERIALS AND METHODS
Approval was granted for this project by our Institutional Human Ethics Committee. Participants were chosen from records of MH families at the Royal Melbourne Hospital between 1977 and 2004. The majority were referred after an episode of possible MH and as far as possible these episodes were given a clinical grading score 7 . Clinical details are outlined in Tables 1 and 2. The method of contracture testing changed in 2001 to the EMHG IVCT 8 . Prior to this the criteria carbogen bubbled through a saturated solution of halothane in water (RMH protocol). Four patients were included who had positive caffeine halothane contracture tests 9 performed in another institution. While most subjects were MHS according to the above criteria, we also included four malignant hyperthermia equivocal (MHE) subjects. MHE was of the test method used, so that a result was considered MHE if they had a threshold response to caffeine or halothane but not both.
After appropriate provision of information and written consent, blood was collected and DNA extracted. 
Mutation detection
Genomic DNA was extracted from unclotted blood using the Nucleon DNA extraction kit of genomic DNA was performed with a standard polymerase chain reaction (PCR) method using Hotstar TAQ (Qiagen, Valencia, CA), consisting of a denaturation at 95°C for 15 minutes, followed by 35 cycles of 95°C for 30 seconds, annealing at 55 or 59°C for 30 seconds (optimised for each primer extension at 72°C for 10 minutes. The PCR mixture contained 50 ng DNA, 5 μl 2 mM deoxyribonucleotide triphosphates (dNTPs) (lithium salts), 5 μl 10x Hotstar Buffer, 3 or 5 μl additional 25 mM MgCl 2 , 5 or 10 pmol of each primer (forward volume of 50 μl. The exact composition of the PCR reaction mixture was optimised for each primer pair individually. Primer pairs were prepared for exons 1, 2, 3, 4-5, 6, 7, 8-9, 10-11, 12, 13, 14-16, 17, 18, 19, 20, 38, 39, 40-41, 42, 43, 44, 45 , 46-47, 85-87, 98-99, 100-101, 102, 103-104 of the RYR1 gene which account for the 'hot-spots' of known MH causative mutations. Primer sequences are presented in Table 3 .
The PCR products were sequenced in forward DYEnamic ET dye terminator kit (Amersham Despite meeting the above criteria, functional analysis of these novel mutations was beyond the scope of this project, so novel mutations cannot yet be proven as causative.
Haplotype analysis
Haplotype analysis was carried out using the chromosome 19 microsatellite repeat sequence markers D19S228, D19S557, D19S897, D19S421, D19S422, D19S881 10 labelled with either 6-carboxy Fluorescein (FAM) using the same Hotstar TAQ PCR method as for mutation detection. The primer sequences are presented in Table 4 .
The reactions were analysed on the MegaBACE 1000 using 550 6-carboxy-X-rhodamine (ROX) as (Amersham, U.K.).
RESULTS

Mutation detection
Samples of genomic DNA from 38 individuals with known positive IVCTs (MHS or MHE) were but as yet functionally uncharacterised mutations and functionally uncharacterised (novel), mutations samples each contained two functionally uncharacterised mutations. The mutations are presented in Table 5 . None of the mutations was observed in 100 unrelated MHN controls.
IVCT/Genetic concordance
One hundred percent concordance was achieved in all families included in the study as shown in Table 6 . Some families had more than one member with an IVCT result to use for concordance measurement but in half of the cases only one individual in the family had been tested. It is in no way implied that these numbers represent with more than one member studied, but the lack of discordance is satisfying when all the mutations The numbers of IVCTs that could have been or were avoided were recorded for all referred family members in Table 7 .
Haplotype analysis
RYR1 locus were used to determine the haplotypes of each of the families displaying identical mutations. The results are presented for families Two families in this study displayed the MHS and MHN in both families. Haplotyping in these families revealed a common allele, indicating that these families are highly likely to be related, although the common forebear is unknown at this stage. This mutation produces a phenylalanine to leucine substitution at amino acid residue 539, six amino acids along from the published mutations 20 21 , also located in exon 15. This region is highly conserved, being consistent 22 (Figure 4 , middle panel).
codes for a tyrosine to cysteine substitution at amino acid 3933. Although this is not a well-known region for MH causative mutations, there have been reports of mutations in adjoining exons 13 and this is also a highly conserved region of RYR1 ( Figure  4 , lower panel). The closest reported mutation is mutation has been described 23 , which produces an amino acid substitution 17 residues earlier.
asparagine substitution at residue 51, six amino acids after the cysteine 20 and histidine 13 substitutions described for arginine at residue 44, and also in a highly conserved region of the gene (Figure 4 , upper panel). Interestingly, this mutation was found in a family in combination with the previously were observed together in two generations of MHS individuals in the pedigree, and therefore reside effect this mutation may have on MH sensitivity without independent functional analysis. While status and that the compound heterozygote state increasing sensitivity to MH triggers.
Like the study by Monnier et al we have also found at least one family with more than one independent causative mutation, occurring on separate alleles, reinforcing the EMHG guidelines for the use of genetic testing to diagnose MHS but not MHN 24 . Family F demonstrates two mutations tracked to both of the parents of the MHS patient studied. This was discovered by two distinct episodes of clinical MH occurring in relatives of both parents of the index case in this family. possible reasons for this:
We know that mutations exist in regions other than the 'hot-spots' of the RYR1 gene 13, 25, 26 . Linkage analysis indicates a high likelihood of the involvement of several other genes in the pathogenesis of MH. These may include SCN4A (chromosome 17q11.2-q24) 27 , CACNA1S (alpha 1A subunit, dihydropyridine receptor) on Chromosome 1q32 28, 29 , CACNA2 (chromosome 7q21-q22) 30 and other genes located on chromosome 3 and 5 of the human genome. These were not analysed in this study. The quoted specificity of the IVCT using the EMHG protocol is 94% 31 . The specificity of the IVCT in our laboratory is difficult to determine as there were two different methods of IVCT testing, but the possibility exists that in families with only one positive IVCT and a mild or atypical clinical story that there could have been a false positive result. It is also possible that our MHE subjects fall in to this category.
We were able to recruit 47 relatives of mutation positive probands for analysis. Twenty-one of these (45%) would have been able to be diagnosed as MHS by mutation analysis alone if all mutations are proven functional, resulting in a total saving of A$76,000-equating to a 22% reduction in costs (total cost of all having IVCT with no genetic testing available=A$340,000, total cost with genetic testing available and IVCT testing for probands on an initial IVCT cost of A$4000.00 (combining day stay, surgical and anaesthetic costs) at our institution, initial proband DNA sequencing costs of A$500.00 and further screening for known mutations at A$100.00 per person.
The MH status of a child under the age of 10 years was able to be determined in four cases. As • • • muscle biopsy is not performed under the age of 10 years, genetic testing facilitated early diagnosis. In addition, the MH status of two elderly patients who refused muscle biopsy on the grounds of residing in states with no IVCT Unit were diagnosed as MHS avoiding travel related expenses and major inconvenience. The cost savings for future genetic those remote from IVCT testing centres. inclusion of only four MHE subjects (those with an IVCT responsive to caffeine or halothane but not both) as this is a problematic group of patients nition in genetic analysis. Our follow up study sequencing the entire RYR1 using cDNA with the inclusion of more of our MHE subjects will aim to redress this limitation. detection rate in those with more strongly positive contracture tests ( Figures 5 and 6 ).
diagnosis. Other potential explanations for this phenomenon are:
Phenotypes with less strong contracture tests have mutations on other genes coding for different parts of the ryanodine receptor complex. Linkage studies in European and North American families have indicated that this may be one factor in the less than 100% mutation detection rate. There have been over 178 missense mutations 13 identified in all areas of RYR1. This project has been limited to the 'hot-spots'.
One of our secondary aims was to identify those mutations occurring more commonly in the Australian population. While further analysis of the RYR1 gene in patients not displaying a mutation in a 'hot-spot' region and RYR1 investigation of many more families will be needed to meet this aim, we have begun the process, which may help to decide on a limited screening test for RYR1 defects in MHS individuals in this country.
This project has achieved its aims of identifying mutations associated with MH and reducing the number of IVCTs required in those families for MHS diagnosis. We have also added to the pool of likely mutations in RYR1 related to MH.
The discovery of two mutations within one family has further emphasised the importance of only using genetic testing for diagnosis of MHS and not for MHN. Further analysis of the family with two possible causative mutations is required before any conclusions about compound heterozygosity can be made. This study has highlighted the need to functionally analyse new mutations so they can be added to the pool of mutations outlined by the EMHG and used for MH diagnosis. Future attempts at increasing the sensitivity of genetic testing should involve the study of other genes that code for proteins responsible for calcium channel activity as well as more detailed analysis of the RYR1 gene.
